PENICILLAMINE-INDUCED SIGNS OF WILSON DISEASE
A 9-year-old boy with asymptomatic Wilson disease who developed neurologic symptoms after treatment with penicillamine is reported from the Department of Pediatrics, Universita Federico II, Naples, Italy. Initially referred for isolated hypertransaminasemia, and hepatomegaly was the only sign of Wilson disease. The diagnosis was confirmed with abnormal urinary copper excretion and high liver copper. After 10 weeks of treatment with penicillamine (20 mg/kg/day) and pyridoxine (25 mg/day), the child developed a tremor of the upper limbs which became progressively severe and incapacitating. Zinc sulfate (100 mg 3x daily) therapy and omission of penicillamine were followed by marked improvement within 2 weeks and remission of tremor at 4 month and 30-month follow-up. Serum transaminase and urinary copper levels were decreased following zinc treatment. (Porzio S, Iorio R, Vajro P, Pensati P, Vegnente A. Penicillamine-related neurologic syndrome in a child affected by Wilson disease with hepatic presentation. Arch Neurol Sept 1997; 54:1166 -1168 . (Reprints: Salvatore Porzio MD, Dipartimento di Pediatria, Universita "Federico II," via S Pansini 5, 80131 Napoli, Italia).
COMMENT. Penicillamine therapy for Wilson disease may rarely precipitate the onset of neurologic symptoms. The authors cite only 5 previous cases, all adults. Zinc appears to be a satisfactory alternative treatment in a limited series. Other reported side-effects of penicillamine include fever, rash, adenopathy, pyridoxine-responsive optic neuritis, nephrotic syndrome, thrombocytopenia, and leukopenia. (Menkes JH. Textbook of Child Neurology. 3rd ed, Philadelphia, Lea & Febiger, 1985; p93) .
HEREDO-DEGENERATIVE DISEASES

PELIZAEUS-MERZBACHER-LIKE DISEASE
A family with X-linked inheritance and Pelizaeus-Merzbacher-like disease (PMLD), PMD without the proteolipid protein (PLP) mutation, studied at the UMDNJ-Robert Wood Johnson Medicial School, New Brunswick, NJ, had a new locus on Xq chromosome, more than 10 cM away from PLP. A clinical diagnosis of PMD in the proband was made on the X-linked inheritance, congenital onset, nystagmus, slow progression with pyramidal signs, seizures, and psychomotor deterioration. The patient died at 25 years, and neuropathological study showed calcific vasculopathy in the basal ganglia and dentate nucleus and intact myelin. COMMENT. PMD patients having mutations in the PLP gene have an onset of symptoms in early infancy, nystagmus, spastic diplegia, ataxia, titubation, head bobbing, hypotonia, and mental retardation. Classical type I PMD has 'tigroid' or perivascular preserved myelin and a life span up to 25 years, whereas type II PMD has diffuse demyelination and death before 10 years of age. The above report identifies a kindred with PM-Like D, clinically resembling PMD, but with intact myelin and with mutations at a new locus on the X chromosome.
SPINAL MUSCULAR ATROPHY AND ARTHROGRYPOSIS
Four infants with neurogenic arthrogryposis who died of respiratory failure before 1 month of age had DNA testing of autopsy specimens for SMNT gene deletion in a study at the Children's Hospital of Philadelphia, PA, and the Children's Hospital at Dartmouth, Lebanon, NH. All infants had clinical, pathologic, or EMG evidence of motor neuron disease. In addition to anterior horn cell loss, autopsies showed a more extensive neurodegeneration Congenital axonal neuropathy with SMN deletion is reported in three newborn siblings presenting with generalized weakness, asphyxia, facial diplegia, and external ophthalmoplegia, and studied at Pediatric University Hospital, Mathildenstr, Freiburg, Germany (Korinthenberg R, Sauer M, Ketelsen U-P et al. Ann NeurolSept 1997; 42:364-368) . EMG, NCV, and nerve biopsies confirmed an axonal neuropathy. The electrophysiological and biopsy findings, together with the SMN gene deletion, were diagnostic of a severe spinal muscular atrophy, complicated by involvement of brainstem nuclei and sensory nerves. Contrary to accepted criteria, weakness of extraocular muscles and facial weakness do not exclude the diagnosis of SMA.
VASCULAR DISORDERS
FACTOR V LEIDEN MUTATION AND NEONATAL STROKE
Three infants with familial factor V Leiden mutation and neonatal cerebrovascular disorders are reported from the Children's Hospital of Philadelphia, PA. One had placental thrombosis. Activated protein C resistance caused by factor V Leiden mutation is an important cause of in utero ischemic infarction and hemorrhagic stroke and may present with neonatal hemiplegic cerebral palsy. (Thorarensen O, Ryan S, Hunter J, Younkin DP. Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis. Ann Neurol Sept 1997; 42:372-375 COMMENT. Infants with hemiplegic cerebral palsy caused by a vascular accident should be tested for factor V Leiden mutation, especially if a parent
